Avalo Therapeutics (AVTX) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $8.0 million.
- Avalo Therapeutics' Total Current Liabilities fell 8686.09% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 8686.09%. This contributed to the annual value of $7.0 million for FY2024, which is 5071.46% up from last year.
- Per Avalo Therapeutics' latest filing, its Total Current Liabilities stood at $8.0 million for Q3 2025, which was down 8686.09% from $9.3 million recorded in Q2 2025.
- Avalo Therapeutics' Total Current Liabilities' 5-year high stood at $215.7 million during Q1 2024, with a 5-year trough of $4.6 million in Q4 2023.
- Over the past 5 years, Avalo Therapeutics' median Total Current Liabilities value was $19.0 million (recorded in 2021), while the average stood at $32.6 million.
- Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 91039.13% in 2024, then tumbled by 9739.68% in 2025.
- Avalo Therapeutics' Total Current Liabilities (Quarter) stood at $19.9 million in 2021, then grew by 11.19% to $22.1 million in 2022, then crashed by 79.12% to $4.6 million in 2023, then skyrocketed by 50.71% to $7.0 million in 2024, then rose by 14.54% to $8.0 million in 2025.
- Its last three reported values are $8.0 million in Q3 2025, $9.3 million for Q2 2025, and $5.6 million during Q1 2025.